UK +44 (0)1865 849841
Malaysia +60 3 2117 5193
  • Bridging The Policy-Practice Divide In Genome-Editing For Agriculture

    Regulation of emerging technology such as genome editing has mainly focused on responding to the consequences of innovation.

  • Four challenges in developing AI algorithms for medical imaging

    With so much emerging on the scene and the inherent technical challenges involved in extracting data from images, what we really want to be focusing on is this question: how robust and reliable is the application itself?

  • The top 4 challenges for microbiome companies – NIZO

    Microbiome research is abundant and profoundly inspiring. But despite the promise, companies in the field face challenges.

  • How do we build the solutions that will transform healthcare’s future?

    We are building the solutions that will revolutionise healthcare in the future: solutions that will transform the trust relationship between the industry and patients.

The benefits of network-driven drug discovery

e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.

Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.

Read More

Controlling the fate of cancer cells with SF3B1 modulators

Andrew Cook has worked in the pharmaceutical industry for over 20 years. Throughout his career, he has endeavoured to do things differently, a little out of the ordinary, leading him to his work at H3 Biomedicine on splice modulators. “Part of the reason it attracted me” he says, “is it’s so different. It’s a natural product-based drug discovery effort, and I had never done that before”.

Read More

Microbial solutions to improve crop growth, crop protection, and crop yield

Gregory Maloney, Senior Scientist at Novozymes BioAg will be hosting a roundtable discussion at the Partnerships in Biocontrol, Biostimulants & Microbiome Congress: USA on navigating the regulatory landscape of biological product development. We spoke to him ahead of the congress about his work.

Read More

Presentation slides from the 6th Microbiome R&D & Business Collaboration Forum

Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides available from Finn Terge Hegge, Angela Sessitsch, Evelina Munukka and Jonathan de Jonge.

Read More

A new kind of pheromone to control agricultural pests

Karl Cameron Schiller is co-founder of Pheronym, a Davis-based agriculture biotech start-up using a new kind of pheromone from microscopic roundworms called nematodes to control agricultural pests. We asked him about his work.

Read More

Going back to biology and the hype of AI in pharma

With a background in pharmacology, toxicology, molecular cell biology and genetics, Rangaprasad Sarangarajan joined BERG Health in 2010 as head of R&D.

In the initial years of the company, he aided in the conception, design, and implementation of the paradigm of looking at human biology, use of technology to generate molecular signatures, and the use of artificial intelligence-based analytics for understanding the complexity of biology, identifying of targets, and developing of drugs, and its utility in clinical development.

Read More

Navigating the regulatory landscape for agricultural products

Terry Stone has worked in agricultural products for almost 30 years and has experience in both research and regulatory affairs. He is currently Vice President of Regulatory Affairs and Sustainability Programs for Agrinos, where he works with industry associations in the US and the EU to develop a regulatory framework for plant biostimulants. We spoke to him about his work.

Read More

Excellence in Breeding: developing breeding programs in Africa and South Asia

Kelly Robbins is Assistant Professor at Cornell University. He started his career in animal breeding and later went on to work as a quantitative geneticist at a large private seed company. We spoke to him ahead of his presentation at the 7th Plant Genomics and Gene Editing Congress: USA.

I came to Cornell University as director of a large project funded by the Bill and Melinda Gates Foundation called the Genomic Open-Source Breeding Informatics Initiative (GOBII for short).

With the cost of sequencing rapidly declining, it seems inevitable that routine of genomic information in breeding programs in Africa and South Asia will become more prevalent. However, there are certain capabilities, tools, and technologies that need to be in place to be able to exploit this type of information effectively and use it to drive higher rates of genetic gains.

Read More

The benefits of network-driven drug discovery

e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.

Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.

Read More

Controlling the fate of cancer cells with SF3B1 modulators

Andrew Cook has worked in the pharmaceutical industry for over 20 years. Throughout his career, he has endeavoured to do things differently, a little out of the ordinary, leading him to his work at H3 Biomedicine on splice modulators. “Part of the reason it attracted me” he says, “is it’s so different. It’s a natural product-based drug discovery effort, and I had never done that before”.

Read More

Presentation slides from the 6th Microbiome R&D & Business Collaboration Forum

Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides available from Finn Terge Hegge, Angela Sessitsch, Evelina Munukka and Jonathan de Jonge.

Read More

Going back to biology and the hype of AI in pharma

With a background in pharmacology, toxicology, molecular cell biology and genetics, Rangaprasad Sarangarajan joined BERG Health in 2010 as head of R&D.

In the initial years of the company, he aided in the conception, design, and implementation of the paradigm of looking at human biology, use of technology to generate molecular signatures, and the use of artificial intelligence-based analytics for understanding the complexity of biology, identifying of targets, and developing of drugs, and its utility in clinical development.

Read More

How CRISPR will guide the way to better cancer therapies

This article was originally published on Open Targets and is republished with kind permission.

For many cancers we don’t have an effective treatment option, and worse still, a lot of the therapies that we use are just not good enough. We need better cancer therapies, and we need them now.

The reason we need new therapies is actually the reason why I got into cancer research. It goes back to when I was only 17 when my Mam was diagnosed with acute myeloid leukemia (AML). She went through her treatment, chemotherapy, with another 12 patients, and unfortunately she was the only one who survived.

Read More

Increasing plant protein digestion in an in vitro model

Population increases and patterns of consumption will put pressure on animal protein supply and price over the coming decades. Plant proteins are a viable alternative, but have a lower digestibility then animal proteins.

Read More

The Liquid Biopsy Workflow

Anders Stahlberg works both in the academic setting as Associate Professor at the University of Gothenburg and in the clinical setting at Clinical Genetics & Genomics, Sahlgrenska University Hospital. Together with his colleagues, this means all aspects of circulating cell-free tumour DNA are covered; from basic science and development, understanding why and how liquid biopsies should be undertaken, to clinically focused questions that the patient will hopefully benefit from.

Ahead of the Liquid Biopsies Congress later this year, we spoke to him about his work.

Read More

Microbiome R&D & Business Collaboration Forum presentation slides

Following the Microbiome R&D & Business Collaboration Forum, we have made the following presentation slides from Karoline Faust, Dirk Hadrich, Lesley Hoyles & Jos Seegers available.

Read More

Microbial solutions to improve crop growth, crop protection, and crop yield

Gregory Maloney, Senior Scientist at Novozymes BioAg will be hosting a roundtable discussion at the Partnerships in Biocontrol, Biostimulants & Microbiome Congress: USA on navigating the regulatory landscape of biological product development. We spoke to him ahead of the congress about his work.

Read More

A new kind of pheromone to control agricultural pests

Karl Cameron Schiller is co-founder of Pheronym, a Davis-based agriculture biotech start-up using a new kind of pheromone from microscopic roundworms called nematodes to control agricultural pests. We asked him about his work.

Read More

Navigating the regulatory landscape for agricultural products

Terry Stone has worked in agricultural products for almost 30 years and has experience in both research and regulatory affairs. He is currently Vice President of Regulatory Affairs and Sustainability Programs for Agrinos, where he works with industry associations in the US and the EU to develop a regulatory framework for plant biostimulants. We spoke to him about his work.

Read More

Excellence in Breeding: developing breeding programs in Africa and South Asia

Kelly Robbins is Assistant Professor at Cornell University. He started his career in animal breeding and later went on to work as a quantitative geneticist at a large private seed company. We spoke to him ahead of his presentation at the 7th Plant Genomics and Gene Editing Congress: USA.

I came to Cornell University as director of a large project funded by the Bill and Melinda Gates Foundation called the Genomic Open-Source Breeding Informatics Initiative (GOBII for short).

With the cost of sequencing rapidly declining, it seems inevitable that routine of genomic information in breeding programs in Africa and South Asia will become more prevalent. However, there are certain capabilities, tools, and technologies that need to be in place to be able to exploit this type of information effectively and use it to drive higher rates of genetic gains.

Read More

Improving crop production through understanding the soil microbiome

Sarah Strauss is a soil microbial ecologist at the University of Florida. Her interests lie in understanding the interactions between soil microbes and crops, with the hope that improved understanding will benefit crop production.

We spoke to her about her work ahead of her presentation at the 4th Partnerships in Biocontrol, Biostimulants & Microbiome Congress: USA.

The interactions between soil microbes and plants are still very much uncharted territory, which makes it an exciting area of study. This is especially the case for the interactions between soil microbes and crops in agricultural systems. For example, we know that there are bacteria and fungi that can influence plant growth or soil nutrient availability, but most of those studies have been done with only a few plant species or under very specific growing conditions. Much of my research is looking at what interactions are occurring between specific crops in field conditions – and how those interactions might differ based on specific conditions or crops in a farmer’s field.

Read More

The Plant Genomics and Gene Editing Congress Presentation Slides

Following the Plant Genomics and Gene Editing Congress: Europe, we have made the following presentation slides from Ana Atanassova, Ian Bancroft, Nigel Halford and Kim Hammond-Kossack available.

Read More

Enhancing Photosynthesis: a Big Deal

The PhotoSeed Technology

Enhancing photosynthesis is a critical step to increasing crop yields. This complex 156 step biochemical process has been the subject of many studies in multiple crops. While some step wise gains have been made, the true potential for increasing photosynthesis has not been realized potentially due to the negative feedback mechanisms that exist within plants to regulate this process.

Read More

Positive Regulatory Developments for the U.S. Ag Tech Industry

2019 may prove to be propitious in terms of meaningful improvements to the regulatory strictures facing agricultural biotech and biologically based products.

In a move that will hopefully lead to positive changes in the regulatory situation facing ag biotech products, on June 11, 2019, President Trump signed an Executive Order directing the heads of the U.S. Department of Agriculture (USDA), Environmental Protection Agency (EPA), and Food and Drug Administration (FDA) to take specific steps to streamline and improve the regulatory processes applicable to the products of agricultural biotechnology.

Read More

Examining Blockchain Systems & Designing Smart Contracts

The blockchain has the potential to enable the collaboration between patients, researchers, and care providers to provide individualised care for patients, but how can this technology be harnessed in a practical way?

This was one of the key questions that was asked at the Blockchain in Healthcare Congress and we had the pleasure of welcoming an array of expert speakers from pharma, academia, and industry to provide the answer.

Read More

The role of extrinsic motivation in sports and physical activity

Motivation is one of the most significant psychological concepts in many areas of life – from work and education to achieving personal goals. In sports and physical activity, motivation plays an especially important part due to the fact that, to millions of people worldwide, staying fit and active is not an obligation or a professional prerequisite, but rather a personal goal. Blockchain technology, together with elements of gamification, may actually help people achieve this goal.

Read More

Conciliating Blockchain and GDPR

Aurélie Bayle is a Data Protection Officer at be-ys: a role she considers to be at the heart of the new legal framework for any company.

Before GDPR came into effect on 25th May 2018, she was working towards global compliance, which involved completing all the steps given by the Article 29 Data Protection Working Party, an advisory board made up of a representative from the data authority of each EU Member State, the European Data Protection Supervisor, and the European Commission. Her duties have included auditing the structures and processes, preparing the data protection impact assessments, checking the compliance of processing activities, analysing the risks of the processing in the medical area, preparing new processes and policies about data protection, and asking data processors about their own compliance.

Read More

When Blockchain Meets the Right to be Forgotten: Technology Versus Law

Over the past few years, the popularity of the blockchain and cryptocurrencies has increased and has reached important notoriety, not only in scientific and IT journals, but also in the media. Although there are many kinds of cryptocurrencies in circulation nowadays, the most popular is Bitcoin.

Read More

Supporting Blockchain Startups: An Open Letter from Katherine Merton

Dear colleagues,

The blockchain technology market is expected to grow to 2.3 billion US dollars by 2021, from 339.5 million US dollars in 2017. [1] With an annual growth rate of 61.5%, it is one of the fastest growing technologies in the healthcare industry.

Read More

The Big List of Microfluidics Companies & Investors

The microfluidic-based devices market has been growing since 2014 due to the increasing point of care testing demand and the miniaturisation of microfluidic chips. 

Read More

What will we do with all this data?

The amount of data we are creating every day has increased exponentially to match the rise in use of smart and connected devices. The internet of things has connected every aspect of our lives to the digital realm: most of these devices operate by tracking your habits, movements, preferences, voice, and more, then logging those habits online. Specifically, the collection of health data has become abundant, because most people now have or wear some sort of device to track daily patterns, steps, cycles, and more. Even our phones often default to track these things for us, whether we choose to enable the function or not.

Read More

How Standards & Standardised Infrastructure Fuel Innovation

It might surprise a lot of people to learn that standards can be viewed as a tool to support innovation, to set businesses free and to focus on the core of their product where their expertise lie. When working with the use of electronic communication systems within the entire healthcare sector, the main focal point is often ensuring a good support for collaboration and work processes.

Read More

Subscribe to Our Newsletter

Get free reports and resources from our world class speakers.
  • This field is for validation purposes and should be left unchanged.

Life Sciences Twitter Feed

Archive